LSC - LifeSciences Consultants’ Post

Introducing the future of medicine with eMedica! 🚀 Healing and Monitoring, all on one platform. Discover our cutting-edge medical device and its advanced treatment methodology. Your go-to source for critical healthcare information. Join us in shaping the future of healthcare. https://lnkd.in/dCVrUhUy #eMedica https://lnkd.in/e4MB25R #HealthcareInnovation #MedicalAdvancements #Investing #Investment #finance #Investor #VentureCapital #privateequity #StockMarket #assetmanagement #WealthManagement #portfolio #Stocks #bonds #RealEstateInvesting #startups #AngelInvestor #capitalmarkets #FundManagement #alternativeinvestments #hedgefund #SustainableInvesting #ImpactInvesting #Diversification #ROI (Return on Investment) #DueDiligence #FinancialPlanning #EconomicOutlook #MarketAnalysis #InvestmentStrategy #MergersAndAcquisitions #riskmanagement

Introducing the future of medicine with eMedica! 🚀 Healing and Monitoring, all on one platform. Discover our cutting-edge medical device and its advanced treatment methodology. Your go-to source for critical healthcare information. Join us in shaping the future of healthcare. https://lnkd.in/dCVrUhUy #eMedica https://lnkd.in/e4MB25R #HealthcareInnovation #MedicalAdvancements #Investing #Investment #finance #Investor #VentureCapital #privateequity #StockMarket #assetmanagement #WealthManagement #portfolio #Stocks #bonds #RealEstateInvesting #startups #AngelInvestor #capitalmarkets #FundManagement #alternativeinvestments #hedgefund #SustainableInvesting #ImpactInvesting #Diversification #ROI (Return on Investment) #DueDiligence #FinancialPlanning #EconomicOutlook #MarketAnalysis #InvestmentStrategy #MergersAndAcquisitions #RiskManagement

Excited to share insights as a panellist at the upcoming online event, "A Smarter Way into the USA", on February 7-8, 2024, that focuses on global expansion for scale-up companies! Join me as we discuss how to facilitate connections with government, trade, and commercial partners, empowering scale-ups to replicate their local success on an international scale. 🌐 #GoToMarket #GlobalExpansion #BusinessStrategy

A panel discussion on #capitalmarkets at #ausmedtech2024 moderated by Bronwyn Le Grice with Steve Burnell Elyse Shapiro Chris Nave and Jo Chaturvedi- Durant : 📉 the heights of investment and valuations in 2021 and the fall-off in 2023 didn’t necessarily affect #medtech 📈with record numbers of FDA approvals of medical devices last year the sector is hopefully positioned for uplift 💭 funds have been holding on to capital and channeling it to their existing portfolio 🩺 medical devices may be a simpler investment proposition but investors can still experience shocks with problems in reimbursement for example 💰potential acquirers are waiting for companies to generate revenue rather than buying on good clinical results 🏹 we have the money here; we need to convince the super funds to unlock it➡️the more wins we have (which requires international capital at this point) the more evidence we have to persuade them 🤝 being partnered with big medtech is accretive in the eyes of investors 🚛 one challenge with the ASX is the lack of specialist analysts and specialised investors 💥 differing views on whether debt is attractive or a deterrent for investors 💰 be aware of non-dilutive funding opportunities here (eg MRFF) and overseas (eg BARDA) 🩺 lay the groundwork for bringing in specialist investors from US/EU by bringing in KOLs from there #venturecapital #asx #capitalraising

Learn more what we at JFBC can help you and your organization with, and why we were reworded “Most Innovative Life Science Service Provider 2023”.   Reach out to me or the JFBC team and we are happy to discuss this further and how we can partner up during 2024!

So much richness in this report from EY — especially the sobering analysis of flagging medtech sector growth. As they say, the first step in fixing a problem is admitting you have one. The root of the problem is a slowdown in true innovation. This is driven primarily by declining R&D investment on the one hand, coupled with a retreat from inorganic growth (M&A) by large strategics in the other. It’s widely accepted that a healthy ecosystem is one where there’s a symbiotic relationship between the larger and smaller players. This is the wellspring of innovation. But the pullback by strategics would tend to harm innovation in the sector more broadly. And the timing of this could not be worse. Here’s the reason why according to EY: “Rapidly evolving technologies, increasingly sophisticated consumer demand for more personalized and convenient health care, pressure to change payment models due to aging populations and a rise chronic disease incidence are all long-term trends that have unavoidable and significant implications for the industry and will ultimately lead health leaders to rethink how care should be delivered in the future.” The current blueprint for medtech innovation hasn’t made a compelling case for its ability to solve these challenges. Especially not in a depressed innovation environment. This won’t change until the industry gets back to its roots and continues to collaborate across the ecosystem to drive the kind of breakthrough innovation needed to get back to differentiated, innovation-driven growth. The path forward is: * a reinvigoration of innovation focus * rebuilding partnerships & collaboration across the ecosystem * attracting the blue-flame thinking (talent) needed to solve the problems posed by the new data-driven, connected, integrated, and patient-centered reality facing the medtech industry. EY offers a point of view on how to do this: “Our vision for the future direction of life sciences is the technology-driven reinvention of the sector, which we call the intelligent health ecosystem (IHE). The IHE is a blueprint for a smart, connected, personalized, patient-centered health care model for the future. Within this new model, health care will be: * Built on ecosystem-wide collaboration and frictionless data sharing between parties * Delivered by a seamless integration of virtual and digital care channels * Enabled by the convergence of new technologies and data, and capable of delivering value for all stakeholders” Easy to say, hard to do. But that’s where true differentiation lies. And the time for leaders to step into the void is now. Exciting times for this massive, vital, and dynamic industry. #medtech #innovation

Here are some key updates on #hlth #hlth23 HLTH and loads of interesting updates from Google Microsoft VALID AI Bessemer Venture Partners and many more !

Words of wisdom from one of our key speakers Klaudia Eriksson Philipp from Pfizer for startups. What should you consider when you're looking to scale? Read her insights from the panel below!